Oxford Biomedica plc (OXBDF)
OTCMKTS
· Delayed Price · Currency is USD
3.927
0.00 (0.00%)
At close: May 2, 2025
Oxford Biomedica Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 128.8 | 89.54 | 139.99 | 142.8 | 87.73 | Upgrade
|
| Revenue Growth (YoY) | 43.84% | -36.04% | -1.97% | 62.77% | 36.95% | Upgrade
|
| Cost of Revenue | 75.78 | 49.81 | 70.81 | 60.16 | 41.66 | Upgrade
|
| Gross Profit | 53.02 | 39.73 | 69.18 | 82.64 | 46.07 | Upgrade
|
| Selling, General & Admin | 91.54 | 116.97 | 23.12 | 13.95 | 11.26 | Upgrade
|
| Research & Development | 4.54 | 11.47 | 94.82 | 47.42 | 40.47 | Upgrade
|
| Other Operating Expenses | -5.25 | -2.8 | -2.31 | -0.87 | -0.8 | Upgrade
|
| Operating Expenses | 90.83 | 125.64 | 115.64 | 60.51 | 50.94 | Upgrade
|
| Operating Income | -37.81 | -85.91 | -46.46 | 22.13 | -4.86 | Upgrade
|
| Interest Expense | -9.84 | -10.67 | -8.69 | -0.86 | -0.87 | Upgrade
|
| Interest & Investment Income | 3.24 | 4.91 | 0.97 | - | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.62 | 1.94 | -7.98 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.67 | -0.53 | -0.07 | -0.03 | -0.04 | Upgrade
|
| EBT Excluding Unusual Items | -45.7 | -90.26 | -62.21 | 21.25 | -5.74 | Upgrade
|
| Merger & Restructuring Charges | -1.5 | - | -5.1 | -1.2 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.07 | 1.02 | 21.39 | - | - | Upgrade
|
| Asset Writedown | - | -99.28 | -0.05 | -0.17 | -0.83 | Upgrade
|
| Pretax Income | -47.27 | -188.53 | -45.98 | 19.88 | -6.57 | Upgrade
|
| Income Tax Expense | 1.34 | -4.37 | -0.82 | 0.87 | -0.33 | Upgrade
|
| Earnings From Continuing Operations | -48.61 | -184.16 | -45.16 | 19.01 | -6.25 | Upgrade
|
| Minority Interest in Earnings | 5.42 | 26.67 | 6 | - | - | Upgrade
|
| Net Income | -43.19 | -157.49 | -39.16 | 19.01 | -6.25 | Upgrade
|
| Net Income to Common | -43.19 | -157.49 | -39.16 | 19.01 | -6.25 | Upgrade
|
| Shares Outstanding (Basic) | 103 | 97 | 95 | 83 | 80 | Upgrade
|
| Shares Outstanding (Diluted) | 103 | 97 | 95 | 86 | 80 | Upgrade
|
| Shares Change (YoY) | 7.15% | 1.82% | 10.76% | 7.10% | 9.95% | Upgrade
|
| EPS (Basic) | -0.42 | -1.63 | -0.41 | 0.23 | -0.08 | Upgrade
|
| EPS (Diluted) | -0.42 | -1.63 | -0.41 | 0.22 | -0.08 | Upgrade
|
| Free Cash Flow | -58.16 | -38.35 | -28.91 | 15.99 | -10.24 | Upgrade
|
| Free Cash Flow Per Share | -0.56 | -0.40 | -0.30 | 0.19 | -0.13 | Upgrade
|
| Gross Margin | 41.17% | 44.37% | 49.42% | 57.87% | 52.52% | Upgrade
|
| Operating Margin | -29.35% | -95.95% | -33.19% | 15.50% | -5.54% | Upgrade
|
| Profit Margin | -33.53% | -175.89% | -27.97% | 13.31% | -7.12% | Upgrade
|
| Free Cash Flow Margin | -45.16% | -42.83% | -20.65% | 11.20% | -11.68% | Upgrade
|
| EBITDA | -20.89 | -70.01 | -31.1 | 32.66 | 3.6 | Upgrade
|
| EBITDA Margin | -16.22% | -78.19% | -22.22% | 22.87% | 4.10% | Upgrade
|
| D&A For EBITDA | 16.92 | 15.9 | 15.36 | 10.53 | 8.46 | Upgrade
|
| EBIT | -37.81 | -85.91 | -46.46 | 22.13 | -4.86 | Upgrade
|
| EBIT Margin | -29.35% | -95.95% | -33.19% | 15.50% | -5.54% | Upgrade
|
| Effective Tax Rate | - | - | - | 4.37% | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.